matuzumab
mAbexperimental
Matuzumab is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania — Wikipedia
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2002 (NCT00113581)
Timeline
Indications
Mechanism of action
EGFR inhibitor
The binding of matuzumab to domain III sterically blocks the domain rearrangement that is required for high affinity ligand binding and receptor dimerization.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMatuzumab ↗
- ChEMBLCHEMBL2108038 ↗
Also known as
- emd72000
- emd 72000
- emd 72000
- emd-72000
- emd-72000
- matuzumab
- matuzumab
- matuzumab
- matuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00215644 | Phase 2 | Aug 1, 2005 | Merck KGaA, Royal Marsden Hospital NHS Trust |
| NCT00111839 | Phase 2 | May 1, 2005 | Merck Serono, The University of Texas, Dallas, University of North Carolina at Chapel Hill |
| NCT00073541 | Phase 2 | Apr 1, 2003 | Merck Serono |
| NCT00113581 | Phase 1 | Oct 1, 2002 | Merck KGaA, Royal Marsden Hospital NHS Trust |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 2 | 2 | 2 | 2002 |
| Merck Serono | For profit | 2 | 2 | 1 | 2003 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 2 | 0 | 2 | 2002 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2005 |
5 organizations
Page 1 / 1